Strategic Investment from Thermo Fisher (NYSE:TMO)

Ionpath, is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI™ technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.

Ionpath’s MIBI™ technology is delivering on the promise of spatial proteomics by providing unprecedented insights for translational medicine researchers. Through highly multiplexed, quantitative protein imaging with high sensitivity and true subcellular resolution down to 350 nm, MIBI technology delivers actionable insights of single cells in their complex tissue microenvironment with the throughput and reproducibility required for clinical studies.

More Like This

May 2022
$82 Million

Series C Convertible Preferred

Exclusive Placement Agent

View Details
May 2022

Sale of GeneDx, Inc., a Subsidiary of OPKO Health, Inc. (NASDAQ: OPK) to Sema4 Holdings Corp. (SMFR)

Financial Advisor

View Details
Apr 2022
$225 Million

Senior Secured Term Loan

Sole Placement Agent & Exclusive Financial Advisor

View Details